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Abstract 
The endothelium controls vascular tone not only by releasing NO and prostacyclin but 
also by other pathways causing hyperpolarization of the underlying smooth muscle cells. This 
characteristic was at the origin of the denomination “endothelium-derived hyperpolarizing 
factor” (EDHF). However, this acronym includes different mechanisms. Arachidonic acid 
metabolites derived from the cyclooxygenases, lipoxygenases and cytochrome-P450 
pathways, H2O2, CO, H2S and various peptides can be released by endothelial cells. These 
factors activate different families of K+ channels and hyperpolarization of the vascular smooth 
muscle cells contribute to the mechanisms leading to their relaxation. Additionally, another 
pathway associated with the hyperpolarization of both endothelial and vascular smooth 
muscle cells contributes also to endothelium-dependent relaxations (EDHF-mediated 
responses). These responses involve an increase in the intracellular Ca2+ concentration of the 
endothelial cells followed by the opening of Ca2+-activated K+ channels of small and 
intermediate conductances (SKCa and IKCa). These channels show a distinct subcellular 
distribution, SKCa are widely distributed over the plasma membrane while IKCa are 
preferentially expressed in the endothelial projections toward the smooth muscle cells. 
Following SKCa activation, smooth muscle hyperpolarization is preferentially evoked by 
electrical coupling through myo-endothelial gap junctions, while following IKCa activation, 
potassium efflux can activate smooth muscle Kir2.1 and/or Na+/K+-ATPase. EDHF-mediated 
responses are altered by aging and various pathologies. Therapeutic interventions can restore 
these responses suggesting that the improvement of the EDHF pathway contributes to their 
beneficial effect. A better characterization of EDHF-mediated responses should allow 
determining whether or not new drugable targets can be identified for the treatment of 
cardiovascular diseases. 
Key words: endothelium, cell membrane potential, potassium channels, myo-endothelial gap 
junctions, EDHF. 
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INTRODUCTION 
Endothelial cells synthesize and release factors that regulate angiogenesis, inflammatory 
responses, hemostasis as well as vascular tone and permeability. The endothelium maintains 
the balance between inhibition and promotion of the proliferation and migration of smooth 
muscle cells, between prevention and stimulation of the adhesion and aggregation of the 
platelets, between thrombogenesis and fibrinolysis as well as between vasodilatation and 
vasoconstriction. Upsetting this tightly regulated balance leads to endothelial dysfunction 
[1,2] (figure 1). 
Endothelium-dependent relaxations/vasodilatations in response to neuro-humoral 
mediators and physical forces, such as the shear stress exerted by the flowing blood, are 
generally attributed to the release of nitric oxide (NO) and/or prostacyclin (PGI2) [3-6]. 
However, in numerous blood vessels from different species, including the human, these 
responses cannot be totally explained by the release of these two mediators. The relaxations 
observed in the presence of inhibitors of cyclooxygenases and NO-synthases are often 
associated with the hyperpolarization of the vascular smooth muscle cells and were first 
attributed to a non-characterized endothelial factor termed EDHF for endothelium-derived 
hyperpolarizing factor. The acronym “EDHF” turned out to be confusing because it implies 
that a single diffusible substance mediates this type of endothelium-dependent relaxation. In 
fact NO itself, but also numerous identified putative endothelium-derived factors including 
carbon monoxide (CO), hydrogen sulfide (H2S), reactive oxygen species, peptides and 
arachidonic acid metabolites derived from the cyclooxygenases (COX), lipoxygenases and 
cytochrome P450 monooxygenases pathways can hyperpolarize the underlying smooth 
muscle cells [1]. 
Hyperpolarization decreases Ca2+ influx, either by reducing the open probability of 
voltage-dependent calcium channels (CaV) or the CaV-dependent activation of the 
sarcoplasmic reticulum, which is a powerful mean to produce the relaxation of vascular 
smooth muscle cells [7-9]. 
Another pathway, which does not involve the synthesis and the release of a factor per se, 
is associated with the hyperpolarization of both the endothelial and the vascular smooth 
muscle cells (EDHF-mediated responses) and contributes also to endothelium-dependent 
relaxations. These responses involve an increase in the intracellular Ca2+ concentration of the 
endothelial cells followed by the opening of Ca2+-activated K+ channels of small and 
intermediate conductance (SKCa and IKCa, respectively) and the subsequent hyperpolarization 
of these cells. Then, the endothelium-dependent hyperpolarization of the underlying smooth 
muscle cells can be evoked by direct electrical coupling through myo-endothelial junctions 
and/or the accumulation of K+ ions in the intercellular space between the two cell types [1]. 
The present review will briefly summarize the hyperpolarizing effects of the various 
endothelial-derived factors and focus on this latter mechanism, i.e. EDHF-mediated 
responses. 
 
ARACHIDONIC ACID METABOLITES 
CYCLOOXYGENASES  
In the endothelial cells, PGI2 is the principal cyclooxygenase-derived metabolite of 
arachidonic acid. When activating its preferential receptor, the IP receptor, PGI2 is a potent 
antithrombotic and antiplatelet agent and is generally a vasodilator substance [3]. The deletion 
of PGI2-synthase generates hypertensive mice with arterial sclerosis while, in response to 
stress or injury, the IP receptor knockout animals show enhanced platelet activation, 
thrombosis, intimal hyperplasia, atherosclerosis, restenosis, and are prone to ischemia-
reperfusion injury [10]. 
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The vascular relaxation to PGI2, or its synthetic analogues, is often associated with the 
concomitant hyperpolarization of the smooth muscle cells, which, depending on the blood 
vessels and the species, can involve the opening of various populations of potassium channels 
[11,12]. Therefore, in numerous vascular beds, PGI2 can act as an endothelium-derived 
hyperpolarizing substance [13]. Since inhibitors of cyclooxygenases abolish the basal and 
stimulated generation of PGI2, and potent and specific antagonist of the IP receptor block its 
vasodilator responses [14,15], the contribution of PGI2 in endothelium-dependent responses 
can reasonably be assessed. This prostaglandin plays a role in flow-mediated vasodilatation 
[16,17]. However, its contribution to acute endothelium-dependent relaxations in response to 
neuro-humoral mediators is often minimal [1] or can only be observed when the other 
endothelial pathways have been inhibited [18,19]. The contribution of PGI2 to endothelium-
dependent responses is increased in eNOS knockout mice [20,21]. Similarly, in human with 
cardiovascular diseases, COX-2-derived prostaglandins can play a compensatory role for the 
decreased NO bioavailability [22,23] possibly explaining some of the detrimental 
cardiovascular effects associated with COX-2 inhibitors [24]. 
However, in aging and in the course of some cardiovascular diseases PGI2, along with 
other prostaglandins, can also act as an endothelium-derived contracting factor by activating 
smooth muscle thromboxane/endoperoxide receptors (TP-receptors) and thus contribute to 
endothelial dysfunction [14,15,25] (figure 1). 
CYTOCHROME P450 MONOOXYGENASES 
Epoxyeicosatrienoic acids (EETs), derived from the endothelial cytochrome P450 2C or 
2J epoxygenases, are generally, but not necessarily, vasodilator agents [26,27] while 20-
hydroxyeicosatetraenoic acid (20-HETE, a metabolite of the cytochrome P450 of the 4A and 
4F family preferentially located in vascular smooth muscle cells) is a potent endogenous 
vasoconstrictor of renal, cerebral, coronary, mesenteric and skeletal muscle arteries [28] 
(figure 1). 
EETs play an important role in endothelium-dependent relaxations either as diffusible 
factors or as essential endothelial intracellular second messenger(s) [29]. When released, they 
can act as an autocrine agent eliciting endothelium and NO-dependent relaxations [30] or 
more generally diffuse toward the underlying vascular smooth muscle cells and produce their 
relaxation [31,32]. In the latter case, 11,12-EET and 14,15-EET, the two predominant 
diffusible isoforms, activate large conductance calcium-activated potassium channels (KCa1.1 
or BKCa) of the vascular smooth muscle cells [33-36]. Experiments performed both in vitro 
and in vivo on human blood vessels suggest a contribution of EETs to endothelium-dependent 
relaxations/vasodilatations in coronary and mammary arteries as well as in peripheral 
muscular and subcutaneous arterioles [37-40].  
Cytochrome P450 metabolites play also an important role in the regulation of the kidney 
circulation and contribute to the long-term regulation of blood pressure and sodium 
homeostasis. EETs regulate not only regional blood flow, but activate KATP channels in 
cardiomyocytes, limit platelet aggregation, exert anti-inflammatory actions and improve 
insulin sensitivity and lipid metabolism. Thus, they can protect the kidney vasculature from 
injury during renal and cardiovascular diseases, exert cardioprotection and prevent/delay 
metabolic syndrome and atherogenesis [41-43]. 
EETs are rapidly metabolized by soluble epoxide hydrolase to form the generally less 
active dihydroxyeicosatrienoic acids (DHETs). In mice, disruption of the soluble epoxide 
hydrolase gene produces no or minor decreases in basal arterial blood pressure [44] but 
protects against myocardial ischemia-reperfusion, heart failure and ischemic stroke [45-47]. 
In rats, soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac 
hypertrophy [48], which in cardiovascular patients is the most commonn cause of heart 
failure. Polymorphisms of soluble epoxide hydrolase (EPHX2) have been associated with 
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coronary artery diseases, ischemic stroke and insulin resistance [43,49,50]. Potent and 
selective inhibitors of this enzyme have been designed and are currently undergoing clinical 
trials for the treatment of hypertension. The additional anti-inflammatory properties of soluble 
epoxide hydrolase inhibitors make them also attractive for the treatment of chronic kidney 
disease in patients with cardiometabolic syndrome [51]. 
LIPOXYGENASES  
In rat and porcine coronary arteries, the 12-lipoxygenase metabolite 12-(S)-
hydroxyeicosatetraenoic acid (12-S-HETE) can be released by the endothelial cells and evoke 
relaxation of the vascular smooth muscle by activating BKCa [52]. 
In rabbit arteries, the generation of 11,12,15-trihydroxyeicosatrienoic acid (11,12,15-
THETA) by reticulocyte-15-lipoxygenase-I contributes to acetylcholine-induced 
endothelium-dependent relaxations [53]. In this species, the age-related decrease in 
hypotension and the endothelium-dependent relaxations induced by acetylcholine are 
mediated by a decreased synthesis of 11,12,15-THETAs, associated with a down-regulation 
of 15-lipoxygenase expression and a reduced activity of the enzyme [54,55]. By contrast, 
short-term hypercholesterolemia, in the absence of atherosclerotic lesions, and chronic 
hypoxia increase endothelial 15-lipoxygenase expression, 11,12,15-THETAs production as 
well as acetylcholine-induced endothelium-dependent relaxations and hypotension [56,57] 
(figure 1). 
However, although a strong case for lipoxygenases derivatives acting as endothelium-
derived hyperpolarizing substance can be built in specific arteries and especially in those of 
the rabbit, most of the EDHF-mediated responses, including that in human arteries, do not 
appear to involve metabolite of arachidonic acid produced by this pathway [1,58].  
ENDOCANNABINOIDS  
In isolated blood vessels or in vivo in anaesthetized animals, endogenous and exogenous 
cannabinoids usually have vasodilator properties and are likely to play a role in cardiovascular 
homeostasis [59]. However, the suggestion that anandamide could be an endothelium-derived 
hyperpolarizing substance has not been substantiated [1,60]. 
 
NO-SYNTHASES 
Three different isoforms of an enzyme are able to synthesize NO from L-arginine and 
molecular oxygen, NO-synthase I (or neuronal, nNOS, NOS-1), NO-synthase II (or inducible, 
iNOS, NOS-2) and NO-synthase III (or endothelial, eNOS, NOS-3). Under various 
circumstances such as the presence of NOS inhibitors, low levels of L-arginine or oxidized 
tetrahydrobiopterin but also under physiological conditions, NO-synthases can generate 
superoxide anion (O2.-), which is reduced to hydrogen peroxide (H2O2), either spontaneously 
or enzymatically by superoxide dismutase (SOD). H2O2 can act locally close to its site of 
production or, since it is an uncharged molecule, diffuse through the cell membrane and act 
on neighboring cells [5,61-63] (figure 1). 
NITRIC OXIDE (NO) 
NO is a potent vasodilator and a powerful inhibitor of platelet adhesion and aggregation. 
The relaxations elicited by NO are generally associated with the stimulation of the cytosolic 
soluble guanylyl cyclase and the subsequent activation of cyclic guanosine monophosphate 
(cGMP)-dependent protein kinase (PKG) [5]. NO regulates the activity of various potassium 
channels and, depending on the vascular beds, the hyperpolarizing effects of NO on vascular 
smooth muscle cells can substantially contribute to their relaxation [1]. The activation of 
BKCa channels by NO contributes to the beneficial effects of currently prescribed drugs 
associated with the L-arginine-NOS-cGMP pathway, for instance NO donors and 
phosphodiesterase inhibitors such as sildenafil [64].  
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In contrast to inhibitors of cyclooxygenase, inhibitors of NO-synthase do not necessarily 
fully inhibit the production of NO. Thus, in their presence, residual NO can still be produced 
by the endothelial cells and contributes to the relaxation and/or hyperpolarization of the 
underlying vascular smooth muscle [65]. Furthermore, NO can also be stored and released 
independently of the activation of NO-synthase [66-68]. Therefore, it seems likely that the 
role of NO as an endothelium-derived hyperpolarizing substance may be underestimated by 
assuming that the presence of an inhibitor of NO-synthases rules out its contribution. A non-
NO- non-PGI2-mediated response should be reported not only when a relaxation and/or 
hyperpolarization is recorded in the combined presence of inhibitors of cyclooxygenases and 
NO-synthases but when this response is still observed with the additional presence of a NO 
scavenger [69]. In in vivo studies in human, complete blockade of NO synthase is difficult to 
achieve (or to demonstrate) and for obvious ethical reasons many of the pharmacological tools 
used to study EDHF-mediated responses cannot be administrated. The limitation of these 
studies should always be kept in mind when interpreting these data. 
In NOS-3 knockout mice, EDHF-mediated responses play a compensatory role for the 
absence of endothelial NO [70] and this adaptation to NO synthase deletion is gender specific 
[71]. Similarly, in resistance arteries from female double knockout mice for NOS-3 and 
cyclooxygenase-1 (COX-1), endothelium-dependent relaxations are preserved by an EDHF-
mediated mechanism while, in arteries from the double knockout males, the endothelium-
dependent relaxations are impaired severely. In genetically modified female mice, the double 
deletion of NOS-3 and COX-1 does not affect mean arterial blood pressure while the 
corresponding males are hypertensive [72].  
HYDROGEN PEROXIDE 
In the mesenteric arteries of mice with disruption of the various NOS isoform genes 
(single NOS-3 knockout, double NOS-1/NOS-3 knockout and triple NOS-1/NOS-2/NOS-3 
knockout) the endothelium-dependent relaxations and hyperpolarizations resistant to 
inhibitors of NO-synthases and cyclooxygenases are progressively reduced as the number of 
the disrupted NOS genes increased [73]. The dependency of the responses resistant to 
inhibitors of NO-synthases and cyclooxygenases towards the NOS systems could not be 
explained by residual NO release but has been attributed to the production of H2O2 [73] 
(figure 1). 
Depending on the tissue, the experimental conditions or the concentrations studied, H2O2 
possesses dilator or constrictor properties, and can hyperpolarize or depolarize vascular 
smooth muscle cells [74]. For instance, in the isolated murine mesenteric artery, H2O2, at 
concentrations lower than 50 µM, produces an endothelium-independent relaxation providing 
that KCa channels are operational but, at the same concentrations, elicits a potent contractile 
response if the activity of these channels is compromised [75]. 
In NOS-disrupted murine arteries, relaxations resistant to inhibitors of NO-synthases and 
cyclooxygenases are sensitive to catalase, the enzyme that dismutates H2O2 into water and 
oxygen, and have been attributed to the NOS-3/Cu,Zn-SOD-dependent formation of H2O2 
[76,77] (figure 1). The maintenance of these endothelium-dependent 
relaxations/hyperpolarizations in NOS-3 knockout mice was explained by the compensatory 
endothelial expression of other NOS genes, the production of H2O2 being preserved up to the 
total disruption of the three NOS genes [73]. Nevertheless, whether or not the decrease in the 
EDHF-mediated responses is directly associated with the disruption of the NOS genes or is 
independently associated with the severe phenotype of these mice, especially with the one 
observed in the triple knockout mice (hypertension, dyslipidemia, myocardial infarction and 
nephrogenic diabetes insipidus) remains to be fully assessed (see also the phenotype of mice 
with deletion of the cystathionine γ-lyase). 
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The involvement of H2O2 in agonist- and flow-induced endothelium-dependent 
relaxations/vasodilatations has been suggested in other vascular beds [78], including human 
mesenteric [79] and coronary arteries [80]. In addition, without actually being released by the 
endothelial cells, H2O2 can enhance EDHF-mediated responses by potentiating calcium 
release from endothelial stores [81]. In various experimental models or in arteries from 
patients with cardiovascular diseases, H2O2 generation can partially compensate the decreased 
NO production, at least in term of endothelium-dependent relaxations, but in the long term 
this production of reactive oxygen species may contribute to vascular oxidative injury [82-
84]. 
Depending on the blood vessels, besides NO-synthases several other endothelial enzymes 
such as cyclooxygenases, lipoxygenases, cytochrome P450 epoxygenases, NADPH oxidases 
and mitochondrial respiratory enzymes can generate superoxide anions and be at the origin of 
H2O2 production [78]. In murine arteries, endothelial oxidases other than NOS do not appear 
to be involved in H2O2-mediated responses [85]. However, in human coronary arterioles flow-
induced endothelium-dependent dilation is associated with H2O2 generated by the 
mitochondrial respiratory chain, while bradykinin-induced endothelium-dependent relaxation 
requires NADPH oxidase-derived H2O2 [86,87]. 
Therefore, in presence of nitric oxide synthases and cyclooxygenases inhibitors, residual 
NO and/or H2O2, both potentially derived from various endothelial NOS isoforms, can act as 
endothelium-derived hyperpolarizing substances. However, in many arteries EDHF-mediated 
responses cannot be attributed to the generation of residual NO or to that of H2O2 [1,74,88].  
 
OTHER GASEOUS MEDIATORS 
Besides NO, CO and H2S are also water soluble low molecular weight gas that readily 
cross lipid membranes and therefore diffuse homogeneously and in a non-polarized manner 
from their production site acting as autocrine and paracrine substances [89]. 
CARBON MONOXIDE (CO) 
 The predominant biological source of CO is from the heme degradation by heme-
oxygenase (HO), either from the constitutive (HO-2) or the inducible (HO-1) isoform, both 
being expressed in vascular smooth muscle and endothelial cells [90,91]. In many physio-
pathological situations the HO-CO pathway compensates for the decrease NO bioavailability 
[91]. CO is a potent vasodilator in most, but not all, vascular beds. The mechanisms of CO-
induced vasodilatation involve the stimulation of soluble guanylate cyclase, the inhibition of 
cytochrome P450-dependent production of 20-HETE and/or the activation of various 
populations of K+ channels [91]. However, CO is also a tonic inhibitor of NOS, by binding to 
its prosthetic heme, and can contribute to endothelial dysfunction [92]. 
HO-1 knockout mice, although normotensive, when subjected to stress or injury show 
exacerbated responses. In contrast, overexpression of HO-1 plays a protective role in 
hypoperfusion and ischemia/reperfusion injury and induction of HO-1 expression by transient 
hemin administration produces a long-lasting normalization of arterial blood pressure in 
spontaneously hypertensive rats (SHR) [93,94]. HO-2 knockout mice are also normotensive 
but stroke damage in response to injuries is accentuated in these animals, indicating that HO-2 
plays an endogenous neuroprotective role in the brain [95]. Carbon monoxide releasing 
molecules have vasodilator, anti-ischaemic and anti-inflammatory effects and may present 
some therapeutic interest in cardiovascular diseases [96]. 
An endothelial production of CO, contributing to endothelium-dependent relaxations in 
response to neurohumoral substances, has been demonstrated only in a limited number of 
arteries and is therefore unlikely to explain most EDHF-mediated responses [1,97,98].  
HYDROGEN SULFIDE (H2S) 
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 Two main enzymes are responsible for the production of hydrogen sulfide (H2S), 
cystathionine β-synthase and cystathionine γ-lyase and both use L-cysteine as substrate. The 
physiological cardiovascular effects of H2S, which are generally linked to the activation of the 
latter enzyme, involve anti-inflammatory and anti-oxidant properties, vasodilatation and a 
decrease in arterial blood pressure [89,99] (figure 1). 
Mice with deletion of the cystathionine γ-lyase, an enzyme expressed in multiple tissues, 
and recently identified in the endothelial cells, are hypertensive and the endothelium-
dependent relaxations of their mesenteric artery in response to methacholine is virtually 
abolished [100]. H2S is produced and released by endothelial cells, in a calcium-dependent 
manner, following neuro-humoral stimulation and evokes relaxation and hyperpolarization of 
vascular smooth muscle cells by activating KATP channels [100,101]. Thus, these results 
suggest that H2S is an endothelium-derived relaxing and hyperpolarizing factor. However, the 
precise role of this mediator needs to be further substantiated. In most studies, the 
endothelium-dependent relaxations of the murine mesenteric artery involve NO release and 
EDHF-mediated responses, which are not necessarily associated with the activation of KATP 
channel [1]. The disappearance of both the NO- and EDHF-mediated component of the 
endothelium-dependent relaxation in cystathionine γ-lyase knockout mice is unexplained at 
present but could be attributed to the increase in homocysteine levels [102,103]. Again, 
whether or not the decrease in endothelium-dependent responses (NO-mediated and EDHF-
mediated responses) is directly associated with the disruption of the cystathionine γ-lyase 
gene or is independently associated with the phenotype of these mice remains to be 
determined (see also multiple NOS-knockout mice).  
H2S donors are currently been synthesized and have therapeutic potential in 
cardiovascular diseases associated with inflammatory processes such as reperfusion injury, 
circulatory shock, atherosclerosis, diabetes and possibly hypertension [97,104,105].  
 
C-TYPE NATRIURETIC PEPTIDE (CNP), 
Endothelial cells can theoretically synthesize numerous vasoactive peptides. Among them 
CNP, a member of the natriuretic peptide family, evokes relaxations and hyperpolarizations of 
vascular smooth muscle cells, including those of human forearm resistance vessels. The 
vasodilator effects of CNP are generally attributed to the activation of natriuretic peptide 
receptors B subtype (NPR-B) on the smooth muscle, followed by the stimulation of 
particulate guanylate cyclase, leading to accumulation of cGMP and the subsequent opening 
of BKCa and KATP channels [106-108]. 
Additionally, it has been suggested that CNP could contribute to EDHF-mediated 
responses. CNP would activate the NPR-C receptor subtype and evoke hyperpolarization of 
the smooth muscle cell via the cGMP-independent activation of G-protein regulated inward-
rectifier K+ channels (GIRK) [109,110]. However, this hypothesis had not been confirmed 
[111-113] and in mice deficient for the NPR-C gene, EDHF-mediated responses are not 
altered [114]. 
Therefore, CNP is unlikely to act as an endothelium-derived relaxing/hyperpolarizing 
substance and contribute to moment-to-moment endothelium-dependent regulation of 
vascular tone. Nevertheless, this peptide plays a key role in preventing smooth muscle 
proliferation, leukocyte recruitment and platelet reactivity. As such, CNP is likely to exert an 
anti-atherogenic influence on the blood vessel walls [115,116]. 
 
EDHF-MEDIATED RESPONSES 
EDHF-mediated responses are endothelium-dependent relaxations resistant to inhibitors 
of NO-synthases and cyclooxygenases, which do not involve one of the identified mediators 
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mentioned above (arachidonic acid metabolites, residual or stored NO, H2O2, CO, H2S, CNP), 
and which require the activation of endothelial calcium-activated potassium channels.  
CALCIUM-ACTIVATED POTASSIUM CHANNELS 
The three subtypes of calcium-activated potassium channels of large (BKCa), intermediate 
(KCa3.1 or IKCa) and small conductance (KCa2.3 isoform or SKCa) are present in the vascular 
wall but with very specific cellular and subcellular localization (figure 2). 
BKCa channels are expressed in virtually all vascular smooth muscle cells [1] while in 
most endothelial cells, when freshly isolated, BKCa channels are at best poorly expressed and 
iberiotoxin-sensitive currents are observed only at very positive potentials [117-119]. In 
smooth muscle cells, BKCa channels, often clustered in groups of 20-100 units, are activated 
by a general increase in intracellular calcium or by calcium sparks, localized elemental 
calcium release events from internal calcium stores, which then generate spontaneous 
transient outward currents (STOC) [120,121]. BKCa channels are often colocalized in discrete 
smooth muscle area with endoplasmic reticulum and form signal complex, physically 
associated with cationic channels such the canonical transient receptor potential channel 1 
(TRPC1) [122] or indirectly associated with the vanilloid transient receptor potential channel 
4 (TRPV4). The Ca2+ influx through TRPV4 preferentially stimulates ryanodine receptors 
located on the endoplasmic reticulum increasing the frequency of Ca2+ sparks. In some 
arteries, EETs-induced hyperpolarization involves the latter Ca2+-signaling complex [36] 
(figure 2). Conversely, there is little evidence for a functional role of SKCa channels in 
vascular smooth muscle cells, although a non-identified apamin-sensitive conductance has 
been reported in some arteries [123-125]. Similarly, in healthy and freshly isolated vascular 
smooth muscle cells IKCa channels are not or very poorly expressed. However, in proliferating 
cells, as seen in culture or after vascular injury, the expression of this channel increases 
dramatically [126,127]. 
By contrast, the IKCa and SKCa channels (especially the SK3 α subunit) are constitutively 
expressed in endothelial cells [117,118,128,129], but show a very different spatial 
distribution. SKCa are diffusely distributed over the plasma membrane with preferential 
locations at sites of homocellular endothelial gap junctions and caveolin-rich domains and are 
associated with various connexins (Cx). IKCa are localized preferentially within the 
endothelial projections through the internal elastic lamina at the sites of myo-endothelial gap 
junctions [113,130-133] (figure 2). 
Agonists that stimulate G protein-coupled receptors and compounds, such as the calcium 
ionophore A23187, thapsigargin, and cyclopiazonic acid, evoke EDHF-mediated responses. 
These substances share the property to increase endothelial intracellular Ca2+ concentration 
and to activate endothelial SKCa channels (blocked by apamin, scyllatoxin, or UCL 1684) 
and/or IKCa channels (blocked by charybdotoxin or TRAM-34) [1]. 1-Ethyl-2-
benzimidazolinone (1-EBIO), a non-specific activator of KCa [134], which activates 
endothelial IKCa and SKCa [118], but not BKCa channels of vascular smooth muscle, 
hyperpolarizes endothelial cells and produces endothelium-dependent hyperpolarization 
[135,136]. Similar results were obtained with more potent analogues of 1-EBIO, such as DC-
EBIO or NS-309 [137,138] and with derivatives of the neuroprotective agent riluzole such as 
SK-20 or SK-31 [139], indicating that activation of endothelial KCa channels and/or 
endothelial cell hyperpolarization elicit(s) EDHF-mediated responses. 
The hyperpolarization of the endothelial cells in turn favours the entry of calcium by 
increasing the driving force for this ion [140,141]. Therefore, endothelial KCa channels are not 
only key players in EDHF-mediated responses but also contribute to the activation of 
calcium-sensitive enzymes such as eNOS and thus to the generation of NO [142,143] (figure 
2). 
HYPERPOLARIZATION OF VASCULAR SMOOTH MUSCLE 
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The involvement of two populations of endothelial KCa channels in EDHF-mediated 
responses has been puzzling for a long time but the discrete role of each channel is now better 
appreciated. 
In the blood vessel wall, gap-junctions link smooth muscle with other smooth muscle 
cells, endothelial with other endothelial cells and in many blood vessels smooth muscle with 
endothelial cells. The connexins (Cx) 37, 40 and 43 are the predominant isoforms of gap-
junction proteins expressed in the vascular wall and, in rodents the Cx37 and Cx40 isoforms 
are involved preferentially in myoendothelial gap junction communication [144-146] (figure 
2). The number of myo-endothelial gap junctions increases with a reduction in the size of the 
artery [147], a phenomenon that parallels the contribution of the EDHF-mediated responses to 
endothelium-dependent relaxations [148,149]. Endothelium and smooth muscle cells can 
communicate via these myo-endothelial gap junctions physically, as Ca2+ and IP3 can diffuse 
from one cell type to another [150-152], and electrically, since depolarization and 
hyperpolarization are conducted bi-directionally from one cell type to the other [151-156]. 
However, endothelium-dependent dilatations do not simply propagate electronically but 
involve a regenerative mechanism [155,157]. Blockers of gap junctions abolish or partially 
inhibit EDHF-like responses in many arteries and in the rat mesenteric artery, antibodies 
directed against Cx40, when loaded selectively in the endothelial cells, block EDHF-mediated 
responses [144,158-160]. Furthermore, in mice, Cx40 is essential for the acetylcholine-
activated regenerative endothelium-dependent vasodilatation [157,162]. Activation of either 
SKCa or IKCa leads to endothelium-dependent hyperpolarizations and relaxations of vascular 
smooth muscle cells, but in quiescent arteries (in the absence of vasoconstrictor stimulation) 
EDHF-mediated responses are associated with the preferential activation of SKCa and the 
contribution of myoendothelial gap junctions [113,131,133,163]. 
Taken into conjunction, the results of these in vitro experiments provide compelling 
evidence for a major contributing role of myoendothelial gap junction in EDHF-mediated 
responses [164]. However, experiments performed in vivo generally failed to demonstrate 
such a significant role for myoendothelial gap junctions [165,166]. The origin of this 
discrepancy is unknown but may involve the type and size of arteries studied in vivo, the 
presence of shear stress, sympathetic innervation and circulating hormones as well as 
confounding factors such as the use of anesthetics which inhibit gap junctions [131,164]. 
Additionally, the efflux of K+ ions associated with the activation of endothelial KCa can 
contribute to EDHF-mediated responses [166]. The resultant moderate increase in the 
extracellular K+ concentration (1 to 15 mM) can provoke the relaxation of vascular smooth 
muscle cells [167] by activating KIR [168] and the Na+/K+ pump [169]. The activation of KIR 
and the Na+/K+ pump overcomes the small depolarizing effects linked to the increase in 
potassium ions per se and the net resultant is hyperpolarization and thus relaxation of the 
smooth muscle cells. This hypothesis was first demonstrated successfully in the hepatic and 
mesenteric arteries of the rat [166] and observed in many other blood vessels including human 
arteries [170-177].  
However, this phenomenon is likely to occur only in specialized microdomains situated 
in the endothelial projections associated with myo-endothelial gap junctions. Section of 
endoplasmic reticulum densely expressing 1,4,5-trisphosphate (IP3) receptors, Cx40, IKCa 
channels and calcium-sensing receptors are colocated in these endothelial projections 
[113,130-133,178]. Repetitive localized calcium events (pulsars), driven by IP3 and/or Ca2+ 
ions (calcium-induced calcium release), originate from these endothelial calcium stores. IP3 
can be generated by the endothelial cells (for instance following acetylcholine stimulation) or 
by the smooth muscle cells (for instance following phenylephrine stimulation). In the latter 
case, IP3 would diffuse toward the endothelial cells (possibly with Ca2+ ions) through the 
myoendothelial gap junctions [113,133,179,180]. The closely situated IKCa channels are 
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activated by these calcium pulsars and the resultant endothelial hyperpolarization can be 
transmitted to the smooth muscle cells either via the myo-endothelial gap junctions, as 
described previously, or be elicited by the K+ ions accumulating in the restricted extracellular 
space surrounding these endothelial projections (figure 3). In the rat mesenteric artery, K+ ion 
accumulation preferentially activates the Na+/K+ pump [113,181]. 
The precise role of the calcium-sensing receptor at the site of these endothelial 
projections is not completely understood. Stimulation of the calcium-sensing receptor results 
in selective IKCa-dependent endothelial hyperpolarization and endothelium-dependent 
vascular smooth muscle hyperpolarization [178,182,183]. In quiescent arteries (in the absence 
of vasoconstrictor stimulation), the calcium-sensing receptor would be fully stimulated by the 
concentration of calcium bathing the endothelial cells and IKCa inactivated [113]. Stimulation 
of smooth muscle (for instance by phenylephrine) opens CaV and, in the small extracellular 
space surrounding myoendothelial projections, could create a localized calcium sink. The 
endothelial calcium-sensing receptor would detect the changes in extracellular calcium and 
allow the recruitment of endothelial IKCa. The subsequent endothelium-dependent 
hyperpolarization would restrain excessive activation of the smooth muscle [113] (figure 3). 
Indeed, reducing the extracellular calcium concentration enables IKCa activation by 
acetylcholine [113,163]. Therefore, endothelial projections and myo-endothelial gap junctions 
are key structures intrinsically associated with extracellular and intracellular calcium 
homeostasis in both endothelial and vascular smooth muscle cells [113,131,133]. 
However, in some blood vessels, K+ does not evoke, or inconsistently produces 
relaxations and hyperpolarizations [136,159,160,184,185], indicating that in these blood 
vessels the contribution of K+ ions in EDHF-mediated responses must be, if anything, 
minimal. The involvement of gap junctions and K+ ions are not necessarily mutually 
exclusive. The relative proportion of each mechanism almost certainly depends on numerous 
parameters including the extracellular concentrations in potassium and calcium ions 
associated with the state of activation of the underlying vascular smooth muscle cells, the 
density of myo-endothelial gap junctions and the level of the expression of the appropriate 
isoforms of Na+/K+-ATPase and/or KIR [1,131]. 
GENETICALLY MODIFIED ANIMALS 
In transgenic mice with SK3 gene expression under the control of dietary doxycycline, 
the suppression of SK3 expression in the endothelial cells depolarizes both the endothelial and 
the vascular smooth muscle cells, reduces the diameter of resistance vessels in situ and 
increases arterial blood pressure, a reversible phenotype upon restoration of endothelial SK3 
expression [186]. Disruption of the IK1 gene reduces the hyperpolarization of endothelial and 
smooth muscle cells in response to acetylcholine and decreases the associated vasodilatation, 
because of a substantial reduction in EDHF-mediated responses. Moreover, the IK1 deletion 
also led to a significant increase in arterial blood pressure and to mild left ventricular 
hypertrophy [187]. In double knockout mice, lacking both SK3 and IK1, an addition of the 
detrimental effects provoked by the deletion of either gene is observed [188,189]. These 
results confirm that in mice endothelial SKCa and IKCa channels are fundamental determinants 
of endothelial hyperpolarization and EDHF signaling and indicate that they actively control 
vascular tone and contribute to the overall regulation of the circulation. 
Connexins 37 and 40 are the predominant gap junction proteins in murine endothelial 
cells [190]. Connexin 40 proteins are involved in endothelial homocellular gap junctions and 
also in heterocellular gap junctions linking endothelial cells not only to smooth muscle cells 
but also to renin-producing juxtaglomerular cells. The presence of the latter gap junction 
communication is required in order to maintain the calcium-dependent inhibitory effects of 
angiotensin II and that of intrarenal pressure on renin secretion and synthesis, suggesting that 
the endothelium is strongly involved in the regulation of the renin system. Mice deficient for 
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connexin 40 are hypertensive. However, alteration in the control of renin release only partially 
explained the hypertension observed in connexin 40 knockout mice [191]. The arterioles of 
these animals also exhibit a reduced spread of dilatation in response to endothelium-
dependent vasodilators and irregular arteriolar vasomotion [192-194].  
Theses results show that deletion of each key molecular component of EDHF-mediated 
responses is associated with hemodynamic alterations suggesting that this endothelial 
pathway contributes to the overall regulation of arterial blood pressure. 
ENDOTHELIAL DYSFUNCTION AND THERAPEUTIC INTERVENTIONS 
Endothelial dysfunction, observed in various cardiovascular diseases, is associated with a 
decrease of NO synthesis and/or a loss of its biological activities. However, alteration of the 
EDHF pathway can also contribute to these endothelial dysfunctions or conversely 
compensate for the loss in NO bioavailability. Alterations of EDHF-mediated responses have 
been reported with aging and under various pathological conditions (hypertension, 
atherosclerosis, hypercholesterolemia, heart failure, ischemia-reperfusion, angioplasty, 
eclampsia, diabetes, sepsis) [1,2,195].  
No drug is available which has been designed to target EDHF-mediated responses. 
Nevertheless, therapeutic interventions, with beneficial effects on the cardiovascular system 
such as angiotensin converting enzyme inhibitors, antagonists of angiotensin receptors and 
phosphodiesterase-3 inhibitors [1,195] can restore these responses, suggesting that the 
improvement of the EDHF pathway contributes to the observed beneficial effect. Similarly, 
various so-called non-pharmacological therapeutic strategies including exercise and 
supplementation with estrogens, omega-3 polyunsaturated fatty acids, polyphenol derivatives, 
potassium and/or calcium help to reverse endothelial dysfunction including blunted EDHF-
mediated responses [1,195]. 
The improvement or restoration of EDHF responses has not been, yet, the direct purpose of 
any pharmaceutical effort. SKA-31, a preferential activator of murine IKCa, potentiates EDHF-
mediated responses in vitro and lowers mean arterial blood pressure in normotensive and in 
angiotensin II–hypertensive mice [139]. However, IKCa channels are required for the 
differentiation of vascular smooth muscle cells, as well for their proliferation and migration 
[126,127,197,198]. Selective blockade of IKCa with TRAM-34 [199] prevents phenotypic 
changes of smooth muscle and coronary artery neointimal formation in two different models of 
post-angioplasty restenosis and the development of atherosclerosis in ApoE(-/-) mice 
[126,198,200] IKCa are also involved in the proliferation of endothelial [201] and various 
cancerous cells [202,203]. Therefore, activators of IKCa may have some unwanted detrimental 
effects.  
Additionally, activation of endothelial TRP and SKCa channels, calcium sensing 
receptors, smooth muscle KIR and/or specific isoform(s) of Na+/K+-ATPase as well as 
facilitating myo-endothelial communication and increasing the expression of appropriate 
connexins, channels and receptors may represent new potential targets. However, the precise 
role of these various molecular elements is far from being completely understood. For 
instance, TRPV4 channel could appear as a promising target in cardiovascular diseases since 
this cationic channel is involved in calcium entry following endothelial stimulation. [204]. 
Indeed, the arterial responses to shear stress critically depend on the activation of this 
endothelial channel and both the NO and the EDHF-mediated components of acetylcholine-
induced vasodilatation are attenuated in TRPV4-deficient mice [205,206]. However, 
GSK1016790A, a specific and potent agonist, which as expected increases endothelial 
intracellular calcium concentration and produces endothelium-dependent relaxations, also 
causes endothelial failure, circulatory collapse and death [207]. Rotigaptide (ZP123), an 
antiarrhythmic peptide that prevents uncoupling of Cx43-mediated gap junction 
communication [208], has no effect on basal vascular tone and does not enhance endothelium-
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dependent or independent vasodilatation in the forearm arterial circulation of healthy subjects 
[209]. Whether or not augmenting Cx43 communication would improve endothelial function 
in patients with vascular disease and whether or not Cx40, in human, would be a more 
appropriate target than Cx43 remain to be determined. 
 
CONCLUSION AND PERSPECTIVES 
Endothelial cells control the tone of the underlying vascular smooth muscle by releasing 
numerous vasoactive substances, including NO, reactive oxygen species, potassium ions and 
metabolites of arachidonic acid (e.g; prostacyclin, EETs, lipoxygenase derivatives). 
Furthermore, the endothelial monolayer behaves as a conductive tissue propagating an 
electrical signal along the axis of the blood vessel by means of homocellular gap junctions and 
throughout the vascular wall itself by means of myo-endothelial gap junctions. Endothelium-
dependent relaxations, independent of the production of NO and prostacyclin, probably play an 
important role in cardiovascular physiology in numerous animal species and in the human. 
They can act as a back up system when NO is inhibited or reduced but this is not necessarily 
the case.  
However, it is often difficult to reach a conclusion as to the true importance of 
endothelium-dependent hyperpolarizations because of the use of unspecific pharmacological 
tools and the lack of electrophysiological measurements. The mechanisms underlying 
endothelium-responses must be carefully dissected in order to be properly identified. The 
synthesis of more selective compounds such as non-peptidic inhibitors and activators of SKCa 
and IKCa may in the future allow the selective blockade/activation of EDHF-mediated 
responses and hence the proper determination of their physiological role in the human 
circulation. The limited information available suggests that if better (i.e. more potent, more 
specific and if possible orally active) pharmacological tools were developed to modulate the 
role of the various molecular constituents underlying EDHF-mediated responses, it may be 
possible to determine whether or not putative cardiovascular targets identified within this 
pathway are drugable. 
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Figure legends 
Figure 1: Endothelium-dependent relaxations and contractions 
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Endothelial cells synthesize and release various vasoactive factors and therefore maintain the 
balance between vasodilatation and vasoconstriction. Upsetting this tightly regulated balance 
contributes to endothelial dysfunction [2]. 
EDRFs: endothelium-derived relaxing factors; EDCFs: endothelum-derived contracting 
factors; COX: cyclooxygenases; SOD: superoxide dismutases; NOS: nitric oxie synthases; 
KCa: calcium-activated potassium channels; P450: cytochrome P450; LOX: lipoxygenases; 
CSE: cystathionine γ-lyase; XO: xanthine oxidase; ECE: endothelin converting enzyme; PGI2: 
prostacyclin; H2O2: hydrogen peroxide; K+: potassium ions; EETs: epoxyeicosatrienoic acids; 
THETA: trihydroxyeicosatrienoic acid; H2S: hydrogen sulfide; PGs: prostaglandins; ROS: 
reactive oxygen species; ET-1: endothelin-1; 20-HETE: 20-hydroxyeicosatetraenoic acid. 
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Figure 2: Calcium-activated potassium channels in the vascular wall and EDHF-mediated 
responses 
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The three subtypes of calcium-activated potassium channels of large (BKCa), intermediate 
(IKCa) and small conductance (SKCa) are present in the vascular wall but with very specific 
cellular and subcellular localization. BKCa channels are expressed preferentially in discrete 
vascular smooth muscle area, smooth muscle plasmerosome, associated with endoplasmic 
reticulum. They form signal complexes with canonical or vanilloid transient receptor potential 
channels 1 (TRPC1 orTRPV4). The IKCa and SKCa channels (especially the SK3 α subunit) 
are constitutively expressed in endothelial cells. SKCa are diffusely distributed over the 
plasma membrane with preferential locations at sites of homocellular endothelial gap 
junctions and caveolin-rich domains and are associated with various connexins (Cx) 
(Endothelial caveolae). IKCa are preferentially localized within the endothelial projections 
through the internal elastic lamina (myo-endothelial gap junctions).  
The activation of endothelial receptors and the shear stress exerted by the flowing 
blood increase endothelial [Ca2+]i. and activates endothelial NO-synthase (eNOS) as well as 
SKCa and IKCa channels. The subsequent endothelial hyperpolarization favors the entry of 
calcium as a positive feedback loop. The hyperpolarization can be conducted through myo-
endothelial gap junctions composed of Cx40 and possibly Cx37 to the underlying vascular 
smooth muscle. Additionally, accumulation of potassium ions in the intercellular space can 
hyperpolarize the smooth muscle cells by activating Na+/K+-ATPase and inwardly rectifying 
potassium channels (KIR). 
EC: endothelial cells; VSMC: vascular smooth muscle cells; ACh: acetylcholine, BK: 
bradykinin; SP: substance P; PE: phenylephrine; RyR: ryanodine receptor; CaV: voltage-
activated calcium channels. 
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Figure 3: Myoendothelial projections 
 
 
VSMC
EC
Ca 2+sparks
RyR
Ca2+ Ca2+
[K+]
K+
eNOS
Shear
stress
TRPV4
TRPC1
BKCa
Smooth muscle 
plasmerosome
SKCa
K+
Na+/K+
ATPase
Myo-endothelial
gap junctions
ACh, BK, SP
Hyperpolarization
Ca2+
Ca2+
IKCa
Cx40
Cx37
Endothelial 
caveolae
Hyperpolarization
Relaxation
Cx37, Cx40, Cx43
KIR
eNOS
SKCa
PE
Ca2+
CaV
Ca2+
NO
Ca2+
TRPV4
Ca2+
Ca2+
[K+]
Na+/K+
ATPase
Myo-endothelial
gap junctions
Ca2+ IKCa
Cx40
Cx37
Hyperpolarization
Relaxation
Ca2+
pulsar
IP3R
KIR
[Ca2+]
CaV
IP3
Ca2+
PE
IP3 Ca2+
CaV
Ca2+
Ca2+
CaSR
VSMC
EC
li l
l
  
I
N a
I
Stimulation of vascular smooth muscle cells by contractile agonists, for instance 
phenylephrine (PE) increases the intracellular Ca2+ concentration via the release of calcium 
from internal stores, through the production of inositol trisphosphate (IP3), and via the entry 
of calcium, through voltage-activated calcium channels (CaV). In order to prevent excessive 
contractions, various negative feedback mechanisms leading to smooth muscle 
hyperpolarization can operate, i.e. the increase in Ca2+ can activate smooth muscle cells BKCa, 
Ca2+ and IP3 can diffuse to the endothelial cells through myo-endothelial gap-junctions and 
activate IKCa (and possibly SKCa) either directly or via the generation of calcium pulsars, 
depletion of Ca2+ in the intercellular space at sites of myo-endothelial projections, via the 
activation of local CaV, can be sensed by the calcium sensing receptor (CaSR) and thus 
unable the activation of IK1. Therefore, intracellular Ca2+ concentrations (and IP3) as well as 
intercellular concentrations of Ca2+ and K+, as surrogates of cellular activation, could finely 
regulate the membrane potential of endothelial and vascular smooth muscle cells and 
therefore vascular tone (schematic based on references 113 and 133). 
EC: endothelial cells; VSMC: vascular smooth muscle cells; Cx: connexins; IKCa: calcium-
activated potassium channels of intermediate conductance; KIR: inwardly rectifying potassium 
channels; IP3R: IP3 receptor;  
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